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INTRODUCTION
Typhoid fever (enteric fever) is a gastrointestinal 
infection caused by Salmonella enterica, serotype 
Typhi or serotypes Paratyphi A, B or C. Humans are 
the only hosts and transmission occurs through the 
fecal-oral route. With the world becoming a global 
village, it is incumbent on health professionals to 
become more knowledgeable regarding the effects 
of this disease on human health. Understanding the 
burden of enteric fever helps with  decision-making 
at all levels of healthcare and could also serve as 
a guide for travelers. The bacteria are present in 
many Southeast Asian countries as well as in Africa, 
Central and South America, and Western Pacific 
countries, where water and sewage sanitation is 
poor. Flood or drought phenomena in endemic 
regions also cause the rapid spread of the bacteria.1
Typhoid fever is not as well understood in Africa 
as elsewhere; largely due to the poor resources for 
laboratory diagnostics and insufficient infrastruc-
ture to support epidemiological and clinical studies. 
These problems are manifestations of the challenges 
faced by a continent already riddled with numerous 
chronic conditions and infectious diseases. The 
inability of governments to provide safe food and 
potable water is a key reason for the high preva-
lence of this disease.2
Despite the genetic similarity of Salmonella typhi 
(SALTY) and Salmonella typhimurium (90% of 
their genes are shared), there remains a poor under-
standing of the genetic differences that underlie the 
ability of SALTY, but not Salmonella typhimurium, 
to cause enteric fever.3 Even though SALTY resides 
(for most of its lifecycle) in the biliary and gastro-
intestinal tract, intestinal inflammation is generally 
uncommon in enteric fever due to the bacteria’s 
ability to evade the immune system. Additionally, 
blood-borne infection leading to systemic sepsis is 
even more rare, for the same reason.
CASE REPORT
We report the case of a 28 years-old male with 
no known co-morbidities who presented with 
septic shock after a ten-day history of abdominal 
pain, malaise, vomiting, and diarrhea. Associated 
symptoms included night sweats, chills, and rigors, 
lethargy, light-headedness, and cough. His abdom-
inal pain was initially peri-umbilical, colicky, and 
persisted for more than 24 hours. 
By day 4 the patient had become constipated 
with worsening weakness, abdominal distension, 
nausea, and vomiting. He was referred to a tertiary 
healthcare facility, in a delirious state, 6 days after 
the onset of symptoms. An abdominal CT scan 
revealed right iliac fossa fluid collections with 
a possible ruptured appendix necessitating an 
emergency laparotomy. Intra-operative findings 
indicated peritoneal inflammation, primarily in 
the right iliac region, involving a severely inflamed, 
thickened terminal ilium, dilated colon, and multi-
ple mesenteric lymph nodes. The appendix was 
located but was only mildly inflamed with no perfo-
ration or necrosis. There was frank pus found in the 
dissected abdominal lymph nodes, but no evidence 
of necrosis or perforation of the small bowel. An 
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ABSTRACT
Typhoid fever, caused by Salmonella enterica, serovar Typhi, is 
restricted to humans as its host and evades the human immune 
system with ease. This quality has been one of the many reasons 
why it is commonly found as an endemic bacterium in emerging 
economies. Also, due to a remarkably low yield from blood cultures 
(median of 1 CFU/mL of blood), Salmonella septicemia is uncommon. 
New evidence gathered together with clinical investigations 
have provided insight into the mechanisms that underlie the 
pathogenesis of typhoid, host restriction as well as antibiotic and 
vaccine susceptibility. However, very little has been done to curb the 
persistence of disease and emergence of resistant strains. We discuss 
a case of Salmonella Septic Shock in the Intensive Care Unit (ICU) that 
takes us through various aspects in diagnosis, the treatment potential 
and the problems surrounding prevention. 
Keywords: typhoid, fever, Salmonella, serovar
Cite This Article: Adu-Gyamfi, R., Hoosain, F., Chetty, S. 2019. Salmonella Typhi – a Quiet Bacteria with a Loud Message: An ICU Case Report. Bali 
Journal of Anesthesiology 3(2): 129-132. DOI:10.15562/bjoa.v3i2.161
Salmonella Typhi – a Quiet Bacteria with a Loud 
Message: An ICU Case Report
Rossi Adu-Gyamfi,1* Fatima Hoosain,1 Sean Chetty2
130 Published by DiscoverSys | Bali Journal of Anesthesiology 2019; 3(2): 129-132 | doi: 10.15562/bjoa.v3i2.161
CASE REPORT
appendicectomy and a transverse loop colostomy 
were performed. 
The patient had to be transferred to the intensive 
care unit (ICU) on adrenaline because of hemody-
namic instability. The admission blood chemistry 
indicated hyponatremia, hypokalemia, and urae-
mic; fulfilling the criteria for acute renal injury. 
He also had leucocytosis and thrombocytopenia. 
Other blood tests indicated deranged liver func-
tions, low calcium, magnesium and inorganic phos-
phate levels with elevated C-reactive protein (CRP), 
admission APACHE II of 31 and SOFA score of 10. 
The blood and intra-abdominal specimens 
submitted for analysis showed gram-negative 
bacilli subsequently identified as SALTY sensitive 
to ciprofloxacin. The patient’s antibiotic therapy 
was changed appropriately. He came off inotro-
pes within 24 hours and was discharged by day 3 
to the general ward. He was managed in isolation 
for 1-week post op and discharged to a step-down 
facility, then discharged home to complete 21 days 
of oral ciprofloxacin. A follow-up blood culture 
and stool samples 6 weeks after admission showed 
no growth for SALTY. On six months follow-up, 
the patient’s stoma has been reversed and he has 
resumed normal activity. 
DISCUSSION
The Kaufmann-White scheme classifies SALTY 
as Group D with O-antigen type O9-12, phase-1 
flagellin type H:d, and Vi capsule positivity. 
Humans are the only known hosts of SALTY, 
however, the organism can survive for several days 
in both freshwater and seawater, and for prolonged 
periods (up to several months) in contaminated 
foods. The infectious dose has been determined 
in human challenge studies to be around 10,000 
organisms, but may vary between individuals and 
in different settings. Recent studies indicate it may 
actually be lower.4 
The Vi capsule has anti-inflammatory properties, 
limiting the deposition of complement compo-
nent CR3 onto the bacterial cell surface, restricting 
immune activation and increasing resistance to 
serum killing. It is also postulated to modulate inter-
actions between LPS and TLR4 and increase the local 
concentrations of the immune-regulatory cytokine 
interleukin 10 (IL-10) in the infected tissues.5
The bacteria invade the intestinal mucosa 
potentially through microfold (M) cells (in the 
 gut-associated lymphoid tissue (GALT) of the 
Peyer’s patches in the small intestine) and establish 
an initially clinically undetectable infection involv-
ing significant systemic dissemination and tran-
sient primary bacteremia.6 The pathogen in some 
cases, cause necrosis of the Peyer’s patch, appearing 
macroscopically as ulcerations commonly seen on 
the anti-mesenteric mucosal lining of the terminal 
ileum. In untreated cases, perforation can occur. 
Mostly, however, it does not trigger a rapid 
inflammatory or diarrheal response. This lack of 
mucosal inflammatory response is what makes 
SALTY disease distinct from most disease caused by 
non-typhoidal Salmonella (NTS) serovars. The aver-
age incubation period after infection is 10 to 14 days 
(range 5 to 21 days). This may not be followed by 
clinical symptoms. Those who go on to develop 
disease become fatigued with a classical stepwise 
manner fever. If left untreated, the temperature may 
remain high (>39 °C) and associated symptoms 
generally, include coughing, vomiting, headache, 
and relative bradycardia or tachycardia.6
Typhoid can be difficult to distinguish clinically 
from other systemic and abdominal conditions, 
such as malaria, appendicitis, abdominal tuber-
culosis, Crohn’s disease or even respiratory tract 
infections. However, a well-trained clinician with 
knowledge of other febrile diseases may observe 
particular clinical patterns, including a spiking 
temperature or Rose spots on the chest.7 Our patient 
manifested a broad range of symptoms which are 
usually rare. These included diarrhea (considered 
to be more frequent in children and HIV-infected 
adults), pulmonary, cardiovascular, central nervous 
system manifestations, and septicemia.
As occurred in our patient, hepatic damage can 
also occur during the acute stage. The life cycle of 
SALTY in the human host makes culture yields 
from the blood samples remarkably low, with a 
median of 1 colony-forming unit (CFU)/mL of 
blood, explaining why SALTY septicemia is a rare 
occurrence.8 Intestinal inflammation is generally 
not regarded as a feature of typhoid due to the 
organisms’ ability to evade immune response in the 
mucosa.5 
However, histological examinations of perfo-
ration sites have identified a combination of acute 
and chronic inflammation close to the perforation 
site. In our patient, there were both macroscopic 
and histological features of inflammation. This may 
indicate that there could have been an impending 
perforation of the bowel. A key feature of typhoid 
is the human carrier state. Individuals in this 
state can shed high levels of SALTY while being 
outwardly asymptomatic and leading a normal life. 
The molecular mechanisms involved in establishing 
the carrier state are not completely understood, but 
colonization of the gallbladder is key to SALTY. 
The carrier state is also associated with intestinal 
re-entry from the gall bladder and this can lead to 
reinfection and subsequent clinical manifestations. 
Gallbladder damage and gallstones can potentially 
contribute to carrier risk. 
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Various studies have found that between 2% 
and 4% of individuals in endemic regions can be 
carriers. Individuals in typhoid endemic regions 
who have never reported having typhoid have been 
found to have elevated anti-Vi antibody levels.9-11 
Mortality rates in untreated typhoid fever can be as 
high as 26%.12 Some studies had shown mortality 
rates of 10% or lower, however, these studies were 
done in carefully managed patients and do not 
represent the reality of managing typhoid in the 
developing world. 
The introduction of chloramphenicol (in 1948), 
ampicillin (1961), co-trimoxazole (1970s), and 
third-generation cephalosporins and fluoroquino-
lones (1980s) reduced the mortality associated 
with typhoid fever considerably. However, resistant 
strains to all three first-line antimicrobial drugs 
emerged prior to the introduction of the latter two 
agents in the 1980s, followed by strains resistant 
to the fluoroquinolones in the 1990s. Extended-
spectrum β lactamase-producing organisms (ESBLs) 
have been increasingly noted in recent times.13 
Fluoroquinolones are a treatment of choice for 
typhoid even in the light of resistance in some cases. 
SALTY induces pathogen-associated molecular 
patterns (PAMPs), via lipopolysaccharide (LPS), 
flagella, and peptidoglycan. There is a drop in 
systemic zinc concentration, the levels of circu-
lating platelets and lymphocytes, as well as hemo-
globin levels.14 Levine MM, et al15 have shown that 
protection can be induced by a variety of different 
vaccines (live attenuated, live and Vi). There are a 
number of live oral vaccines such as Ty21a that have 
been developed from attenuated mutants of SALTY. 
There is both Vi-dependent and Vi-independent 
protective mechanisms in mounting immunity 
against SALTY.15 
Evidence has shown that previous SALTY infec-
tion is not protective in the long term and that 
people can be re-infected within weeks or months 
of a primary episode. Relapse may be a conse-
quence of either recrudescence by the same strain 
from tissues or reinfection from an environmental 
source. Like other resource-constrained countries, 
typhoid fever is endemic within South Africa but 
with an unknown local burden. The epidemic 
potential of typhoid fever has been demonstrated 
in 1993 and 2005 when repeated outbreaks were 
observed in Delmas (Mpumalanga) affecting over 
1 000 cases, and over 400 suspected cases and three 
deaths respectively.
According to the 2015 National Typhoid 
and Paratyphoid Fever Prevention and Control 
Guidelines, South Africa observes a mixed pattern 
of endemic disease and sporadic cases not only in 
the rural setting but also within more developed 
areas of the country. Travelers, both local and 
international, returning from areas with endemic 
transmission are suspected to account for a large 
proportion of cases in South Africa but very little 
is done to screen these individuals. Furthermore, 
clinicians are likely to make a diagnosis of the 
other differentials of typhoid fever. All these factors 
contribute to missed cases, especially in the carrier 
population. Our patient lived in the Eastern Cape 
for 6 months before only presenting 2 weeks after 
returning to Cape Town. The possibility remains 
that the patient was a chronic carrier of SALTY who 
developed the recrudescent illness, or alternatively 
that he was newly infected from a recent contact. 
Questions also remain as to whether the unprece-
dented drought in the Western Cape in 2016-2018, 
could have contributed to the risk infection and if 
so how many other people have also been infected. 
CONCLUSION
There has been enormous progress in our under-
standing of the molecular pathogenesis, evolution, 
epidemiology, and immunology of Salmonella 
infections in recent decades. However, our patient 
presented with an array of clinical features which 
hitherto were considered rare. It might, therefore, 
signify that we may be dealing with a mutated 
species and this should be a matter of concern. 
Instituting measures such as screening of tourist/
travelers, education of clinicians and the general 
populace, provision of clean water, vaccination and 
provision of needed facilities and infrastructure 
to aid in clinical and epidemiological studies on 
SALTY has become even more necessary espe-
cially with the emergence of resistant species. If 
this becomes widespread, treatment options could 
become severely scarce and very expensive. In 
the end, not only would cost of management be 
high, but more lives will be lost. SALTY, survives 
poorly in the environment and is trapped in the 
human population. If emerging economies, includ-
ing South Africa, were to put the right measures 
in place, the control and even elimination of the 
disease can be a possibility.
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